Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Aspart and Insulin Detemir in Type 2 Diabetes
NCT00274274Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2005
- Primary completion
- Nov 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin aspart in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Glycated Hemoglobin A1c at 52 weeks. Started Sep 2005; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00274274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274274.